Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New CAR-T therapy targets tough lung cancer in early trial

NCT ID NCT07246304

Recruiting now Disease control Sponsor: TCRCure Biopharma Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated Jun 13, 2026 · Updated 23 times

Summary

This early-phase trial tests a new treatment called TC-D101 for people with a specific type of advanced small cell lung cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified to attack cancer cells carrying a protein called DLL3. The main goals are to check safety and find the best dose, while also looking at whether the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Jinling Hospital

    RECRUITING

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAR T CELL THERAPY CAR T CELL THERAPY SMALL CELL LUNG CANCER (SCLC) SMALL CELL LUNG CANCER (SCLC)